we identified consecutive patients aged 65 years and older who underwent elective surgery in all Ontario hospitals between Apr. 1, 1992 , and Apr. 1, 2002 . We selected this timeframe because data for these years were available for analysis. We did not include outpatients, those who had day surgery or patients younger than 65 years because the rate of delirium in such circumstances is generally low. To reduce confounding from pre-existing illness, we initially excluded patients with major vascular disease, as evidenced by longterm use of nitrates or β-blockers; however, we relaxed this restriction in a secondary analysis. 16 We received institutional review board approval from the Sunnybrook Hospital Ethics Committee and used confidentiality safeguards of the Institute for Clinical Evaluative Sciences.
Hospital records
We gathered population-based data that counted each patient only once. We analyzed only the first admission for patients who had more than 1 elective surgical procedure during the study interval (analyses based on separate admissions yielded more extreme results and are not reported). In cases where patients were transferred to a different hospital, we counted outcomes according to the original hospital admission. All databases have been used extensively in past research. 17, 18 Statin prescriptions For each patient, we searched prescription records from the Ontario Drug Benefit database for the year before admission, reasoning that statins would customarily be continued perioperatively. We classified people who received 2 or more prescriptions for a statin in the year before surgery (including at least 1 prescription in the 90 days before surgery) as receiving this medication on an ongoing basis. Otherwise, we classified the patient as not receiving a statin. This strategy assured that outcome ascertainment was blind to exposure status, free of reverse-causality bias and conservative in design. 19 The specific statins were atorvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, rosuvastatin and cerivastatin. A previous validation study indicated that the Ontario Drug Benefit database had an accuracy rate of 99% using pharmacy records as the reference standard. 20 
Risk factors for delirium
We gathered data on patient and surgical factors that could potentially contribute to delirium, since established risk factors are controversial. We derived the patients' age, sex and income quintile at the time of admission from the Ontario Registered Persons Database. We identified patients receiving drug therapy for dementia at baseline by assessing whether they were prescribed a cholinesterase inhibitor (e.g., donepezil) in the year before admission. We determined the use of other important baseline neuropsychiatric treatments with prescriptions for antipsychotics (e.g., risperidone), antidepressants (e.g., citalopram) and benzodiazepines (e.g., lorazepam) in the year before admission. We derived information on additional medical treatments from corresponding long-term medications, in accordance with prior research. We determined operative procedures based on the primary surgical procedures, and we classified them as either cardiac or noncardiac. We further distinguished noncardiac surgeries by anatomic site.
Duration of surgery
An innovative aspect of our study was to develop a method for determining the duration of surgery for each patient. This was necessary because prior research indicated that surgical duration was a risk factor for delirium and could vary substantially among patients undergoing the same primary procedure. Our method relied on anesthesiology billing fees linked to individual patients and reimbursed in 15-minute intervals. This method was analogous to estimating anesthesia and surgical times from Medicare claims (Part B data) in the United States. We examined the reliability and validity of the method and found high correspondence to chart review (R 2 = 88%).
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Other medications
We examined other medications prescribed for cardiovascular disease to check whether findings with statins differed from those with other long-term drug therapies that are not known to have pleiotropic properties on the microvasculature. These included nonstatin lipid-lowering medications (e.g., fenofibrate), antihypertensive medications (e.g., hydrochlorothiazide), loop diuretics (e.g., furosemide) and miscellaneous cardiovascular agents (e.g., digoxin). Another set of analyses focused on medications that have indirect effects on the vascular system, including antiplatelet agents (e.g., clopidogrel), orally administered anticoagulants (e.g., coumadin) and other vascular agents (e.g., pentoxifylline). The final set of medications included common drugs that have no major effect on the cardiovascular system (e.g., omeprazole).
Outcome assessment
The primary outcome was the development of delirium during the patient's stay in hospital, based on the International Classification of Diseases codes 293.0-293.9. Surgical complications such as delirium are not always identified by clinicians, recorded in the patient's chart or entered into databases. Hence, the codes are specific (about 98%), but not sensitive (about 35%). 22 A separate chart review of the codes showed a positive predictive value of 100% when compared with doctors' and nurses' progress notes (95% confidence interval [CI] 96%-100%). To check the robustness of our results and to examine the more severe spectrum of postoperative delirium, we considered 7 complex combinations of outcomes: we examined data for patients who experienced postoperative delirium and who also received a computed tomography scan while in hospital, had a wound infection develop during their stay in hospital, experienced a myocardial infarction while in hospital, needed home nursing care after discharge, received ongoing sedatives after discharge, required hospital readmission or died in hospital after surgery.
Statistical analysis
We used the χ 2 test to assess the proportion of patients who experienced delirium, comparing those patients taking statins Research with those who were not taking statins. We used logistic regression to adjust this comparison for patient characteristics, since the time of onset of delirium was not recorded (estimates computed with 95% CIs). We tested generalizability by repeating analyses in 3 more patient groups: those excluded because data on the duration of anesthesia were unavailable, those excluded because of pre-existing major vascular disease and those admitted for emergency surgery. We also tested for selection bias through a secondary analysis of patients who had received a statin in the past but not in the 90 days before surgery. In addition, we examined a cohort matched by propensity score to explore whether the main finding was due to hidden confounding. 23 
Results
A total of 541 827 elective surgeries were performed on 454 084 patients during the study interval. The patients were dispersed across 246 hospitals. We observed no major trends over the years. Overall, we excluded 100 832 patients because anesthesiology records were unavailable. We excluded a further 69 094 patients because they had major vascular disease. This left 284 158 patients for analysis. The typical patient took multiple medications on an outpatient basis; underwent an abdominal, musculoskeletal or urogenital procedure; and had a mean duration of surgery of about 115 minutes. The most common outpatient medications (received by about 15% of patients in each case) were benzodiazepines, angiotensin-converting-enzyme inhibitors, calcium-channel blockers and gastric acid suppressants. About 7% (n = 19 501) of the patients were taking statins before surgery, compared with about 93% (n = 264 657) who were not taking statins before surgery. There was about a 2-year difference in mean age between the 2 groups, with more younger patients than older patients using statins. Otherwise, we found no major differences between the 2 groups in demographic characteristics, use of neuropsychiatric or common noncardiovascular medications, or the number of noncardiovascular surgeries performed ( Table 1) . As expected, use of cardiac medications, cardiac surgeries and peripheral vascular surgeries were more common among patients who used statins than among patients who did not use statins.
Research
Overall, postoperative delirium was diagnosed in 3195 patients (11 per 1000). The risk of delirium was about 30% higher (95% CI 15%-47%) among patients taking statins before surgery (14 per 1000) than among those not taking statins before surgery (11 per 1000, p < 0.001). After adjusting for demographic characteristics, prior admissions and prescriptions and classes of neuropsychiatric medications, we observed a continued increase (OR 1.48, 95% CI 1.38-1.68) in risk of delirium among patients prescribed statins than among those not prescribed statins. We observed a similar increase in risk after adjusting for each cardiovascular and noncardiovascular medication (Figure 1) . The final multivariable model, which adjusted for all the preceding predictors along with the type and duration of surgery, showed a 28% increase in the risk of delirium associated with the use of statins (95% CI 12%-46%, p < 0.001).
The increased risk of delirium associated with the use of statins was evident across a variety of clinical settings. In each analysis, the results showed a detrimental association, although the confidence intervals were broad in many subgroups ( Figure 2 ). Increases in risk were highly consistent among patients who did not take selected neuropsychiatric medications (that were associated with delirium) or selected common medications (that were not associated with delirium). The relative risk with statins was somewhat higher among patients who had noncardiac surgery than among patients who had cardiac surgery, although the baseline risk among those who had cardiac surgery was twice as high as that among patients undergoing noncardiac surgery. The absolute risk of delirium associated with the use of statins was highest among patients older than 70 years and among patients whose surgeries lasted longer than 3 hours (Appendix 1, available online at www.cmaj.ca/cgi/content/full/179/7/645/DC2).
The overall resolution of the multivariable model was reasonable (c-index 0.78, p < 0.001). The strongest single predictor of postoperative delirium was the duration of surgery, which yielded about a 44% increase in risk for delirium for each hour of surgery (95% CI 41%-46%). The other statistically significant predictors were 2 demographic characteristics (age and sex), use of the 4 neuropsychiatric medications and type of surgery (Table 2 ). In contrast, use of angiotensinconverting-enzyme inhibitors, calcium-channel blockers or gastric acid suppressors was not associated with delirium. None of the other long-term cardiovascular and noncardiovascular medications were associated with a statistically significant increase in risk of delirium (Table 3) .
After comparing patients using different statins and receiving different doses, we found no major exceptions. Atorvastatin and simvastatin (2 popular statins with distinct metabolic pathways and half-lives) were each associated with a significantly increased risk of delirium. The odds ratios were 1.68 (95% CI 1.34-2.09) for atorvastatin and 1.46 (95% CI 1.15-1.84) for simvastatin. Pravastatin (the main nonlipophilic statin in our study) was associated with a marginally lower risk of delirium (OR We analyzed patients excluded because of pre-existing major vascular disease (n = 69 094) and found about the same increase in delirium risk among those taking statins compared with those not taking statins (OR 1.26, 95% CI 1.10-1.45). We analyzed patients admitted for emergency surgery (n = 222 615) and found an increase in the risk of delirium among those taking statins compared with those not taking statins (OR 1.24, 95% CI 1.11-1.39). We analyzed patients excluded because the duration of anesthesiology was unavailable (n = 100 832), and also found an increase in delirium risk associated with use of statins (OR 1.18, 95% CI 0.92-1.53) . In contrast, when we analyzed controls who had received a statin in the past but not in the 90 days before surgery (n = 43 152), we found no increase in the risk of delirium associated with use of statins (OR 0.85, 95% CI 0.76-0.96). Finally, in the cohort matched by propensity scores (n = 25 244), we found about the same increase in delirium risk associated with the use of statins (OR 1.30, 95% CI 0.96-1.70).
We explored 7 combinations of severity to test whether delirium contributed to other postoperative complications and whether delirium associated with the use of statins was any less severe than delirium that was not associated with the use of statins. For example, patients who experienced delirium were 6 times more likely than those who did not experience Finally, patients who experienced delirium were 3 times more likely than those who did not experience delirium to die in hospital (3.5% v. 1.0%, p < 0.001). The use of statins was associated with an increased risk of all these severe forms of delirium except the combination of delirium followed by death (Table 4) . Overall, we observed about a 10-day absolute increase in the length of stay in hospital for all patients who experienced delirium (16.1 days among patients who were taking statins v. 6.3 days among those who were not taking statins, p < 0.001). We also observed about a 10% absolute increase in ongoing use of sedatives after discharge (33.9% among patients taking statins v. 23.3% among patients not taking statins, p < 0.001).
Interpretation
We found that 1 in 14 elderly patients in our study cohort were taking statins before undergoing elective surgery and about 1 in 90 experienced delirium after elective surgery. Our results suggested that this association was more than a coincidence, particularly among patients who received higher doses of statins and had longer duration noncardiac surgeries. The association between statins and risk of delirium was distinct and was not observed with other lipid-lowering medications, cardiovascular medications or common drugs that reflect underlying chronic diseases but have no major effects on the cardiovascular system. The correlation prevailed among patients in high-risk subgroups and extended to some more complicated combinations of delirium. The magnitude of the association was substantial, but not as substantial as that between risk of delirium and advanced age, baseline neuropsychiatric drug treatment or prolonged surgery.
The most important limitation of our research was that hidden confounding may have biased our results. For example, we were not able to measure intraoperative hypotension or hypoxemia. However, these factors have not been shown to predict postoperative delirium. 24 We were able to measure patient age and duration of surgery, the 2 most established predictors of delirium in this setting. Our multivariable models also adjusted for many other features that could remain imbalanced in small trials. Our analysis of selection bias suggested that patients taking statins were healthier than patients who were not taking statins. In addition, prior research indicated that unmeasured comorbidities tended to be biased in a manner favouring patients taking statins. 25, 26 Hidden confounding would not explain why our results showed the association between postoperative delirium and the use of statins to be distinct, or why we found no association between delirium and the use of other medications.
Another important limitation of our analysis was outcome definition. That is, the database analyses provided a specific, but insensitive, indicator for postoperative delirium. As such, our study detected extreme cases and underestimated the overall incidence of postoperative delirium, particularly in our analyses that focused on severe combinations of delirium. Consequently, all estimates were biased conservatively, and the absolute increase in risk associated with statin use was understated (assuming no systematic coding bias). If the true incidence of delirium were 10%, 27 for example, an observed odds ratio of 1.28 might amount to a number needed to harm of about 35. The true incidence may be impossible to determine with certainty given the vagaries of distinguishing delirium from other forms of postoperative cognitive dysfunction. 28 Shifts in the distribution of capillary blood flow leading to neuronal ischemia scattered throughout the brain could explain postoperative delirium. However, results of our goodness-of-fit test suggested that other mechanisms also contributed. These mechanisms merit research because delirium could be associated with many of them, including altered isoprenoid metabolism in neurons, inhibition of membrane receptors, toxicity at synaptic clefts, blood-brain barrier dysfunction or drug interactions if such statin pleiotropic effects are tolerated under normal circumstances but not during anesthesia. 29, 30 Our findings are not easily explained as drug withdrawal, because statin cessation generally led to a decreased effect (not rebound harm) and because the observed risk was no lower for the statin with the longest half-life (atorvastatin). 31 The endothelial nitric oxide synthase mechanism emphasized the role of microvascular blood flow autoregulation for preserving neuronal function. 32 Our results are not readily attributable to unmeasured underlying severity of vascular disease for several reasons. First, we observed no adverse association with 20 other medications, each a marker of vascular disease. Second, the analyses adjusted for 30 measured factors and yielded stable results. Hence, a postulated underlying disease would need to be unrelated to all these factors to extinguish the finding. Third, the adverse association was no more or less substantial in our posthoc analysis of patients who had major vascular disease. Fourth, no risk was observed in earlier studies correlating statin use with postoperative myocardial infarction. Hence, the adverse association between the use of statins and postoperative delirium is distinct. Conducting a randomized trial would be a different way to check for bias due to severity of disease. However, randomized trials are generally an unreliable method for studying adverse drug effects, whereas nonrandomized studies are a powerful method for identifying potential toxicity. 33 We caution that our findings do not imply that statins are harmful under normal circumstances. On the contrary, trials involving outpatients show many benefits from long-term statin therapy in cardiovascular care. Furthermore, our primary analysis was restricted to patients who did not have major vascular disease; therefore, we did not assess their potential benefits in preventing myocardial infarction. 34 The implication of our study is that statins, unlike other cardiac medications, might contribute to delirium after elective surgery and can be discontinued temporarily before surgery. Studies suggest that expression of endothelial nitric oxide synthase returns to normal within 2-4 days after interrupting statin therapy. 35 If needed, statin therapy can be reinstated on the first postoperative day, which would re-establish activity of endothelial nitric oxide synthase within 1-2 days (the interval most common for a postoperative myocardial infarction). 36 Such a strategy would have the additional advantage of reducing the risk of inadvertent drug interactions during the hospital stay and reducing the risk of postoperative hepatitis.
Further research could be designed as either a discontinuation trial or a prophylaxis trial, depending on the feasibility of recruitment. We applaud recent calls for more clinical trials in perioperative medicine to directly determine whether medications that are beneficial in the outpatient setting are equally safe in the perioperative setting. 37 The results of our study should inform the design of future studies, bolster recruitment in trials that are currently underway and underscore the need to carefully assess both cardiac and adverse neurologic out- comes after surgery. Until more data are available, a recommendation to temporarily interrupt the use of statins before surgery may be a reasonable compromise.
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